Clinical Trials
120 trialsTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
EVEREST-2
A2 Biotherapeutics Inc.
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers
National Institutes of Health Clinical Center (CC)
TTBF
University of California, San Francisco
OvAR-Y
Washington University School of Medicine
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
GEORGIA
Ohio State University Comprehensive Cancer Center
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
iCaRe2
University of Nebraska
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines, Inc.
Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer
Ohio State University Comprehensive Cancer Center
Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies
National Institutes of Health Clinical Center (CC)
ART-Hypo
Centre hospitalier de l'Université de Montréal (CHUM)
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
GlaxoSmithKline
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
Improving Care for Rural Patients With Solid Tumors
University of Colorado, Denver
SYLVER
GlaxoSmithKline
SCORE
Natera, Inc.
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
Contribution of Preserving the Superior Left Colic Artery to the Vascularization of the Descending Colon Prior to Colorectal Anastomosis During Left-Sided or Rectal Resections for Colorectal or Ovarian Cancer. (Revascularisation Colique)
Institut du Cancer de Montpellier - Val d'Aurelle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
AYAConnect
UNC Lineberger Comprehensive Cancer Center
FIDURA
Sahlgrenska University Hospital
AMPLIFY-201
Elicio Therapeutics
COCHISE
Institut Bergonié
ORACLE
Guardant Health, Inc.
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Esperas Pharma Inc.
TOASTIT
Mayo Clinic
Abdominopelvic Cancer Prehabilitation
Universitat Jaume I
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Stanford University
ROOT
Taproot Health
SPIRIT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
RADIANT
DxTerity Diagnostics
Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.
PILLAR
Jules Bordet Institute
CONTEST
University of Aarhus
Interventions for the Management of Perineal Cancer Pain
Assiut University
PANO
Dublin City University
MIFADORESOL
Institut de cancérologie Strasbourg Europe
HETERERO
Charite University, Berlin, Germany
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
ART-02
Charite University, Berlin, Germany
ASPIRE
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study
M.D. Anderson Cancer Center
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
Perineal Flap Reconstruction Following Surgery for Advanced Pelvic Malignancy
St Vincent's University Hospital, Ireland